Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

3587Background: Biomarkers capable of predicting response to checkpoint inhibitor therapies represent a significant clinical need. Increased tumor neo-antigenic burden has been linked to PD1/PD-L1 ...